文献速递主动脉疾病

多中心Castor单分支覆膜支架治疗胸主动脉疾病的中期结局

Midterm Outcomes of Multicenter Castor Single-Branch Stent Graft Use in the Treatment of Thoracic Aortic Diseases.
PubMed 文献 · J Endovasc Ther · 2024-02-27

该多中心研究纳入2018年5月至2023年6月3个中心使用Castor单分支覆膜支架治疗的106例胸主动脉疾病患者,评估其中期疗效与安全性。技术成功率为98.1%(104/106),随访29.1±17.7个月,2年累积生存率91.0%±3.1%,分支通畅率100%。结论认为Castor单分支覆膜支架在胸主动脉疾病治疗中显示出良好的早中期结局。

要点

  • 技术成功率98.1%(104/106),手术成功率93.4%(99/106)。
  • 随访29.1±17.7个月,2年累积生存率91.0%±3.1%,分支通畅率100%。
  • 近端锚定于1区或2区时,支架相关并发症等指标无显著差异。

核心结论

  • Castor单分支覆膜支架在胸主动脉疾病治疗中显示出良好的早中期结局。
  • 将Castor覆膜支架与其他先进技术联合用于多分支主动脉弓重建是可行的。

研究设计与样本

  • 多中心研究,收集2018年5月至2023年6月3个中心使用Castor单分支覆膜支架治疗的106例胸主动脉疾病患者的临床数据。
  • 评估指标包括技术成功、支架相关并发症、再干预、逆行夹层、内漏、远端支架诱导新发破口(dSINE)、分支通畅率和死亡率,并分析Castor覆膜支架用于弓上多分支重建的结局。

主要发现

  • 技术成功率98.1%(104/106),手术成功率93.4%(99/106)。
  • 再干预率2.8%(3/106),包括1例逆行A型夹层、1例内漏和1例dSINE。
  • 逆行夹层发生率1.9%(2/106),I型内漏发生率1.9%(2/106),新发dSINE发生率2.8%(3/106),分支通畅率100%,死亡率1.9%(2/106)。
  • 平均随访时间29.1±17.7个月,术后2年累积生存率91.0%±3.1%,累积分支通畅率96.2%±2.2%,累积免于支架相关再干预率93.2%±2.8%。
  • Castor覆膜支架近端锚定于主动脉1区或2区时,支架相关并发症、分支通畅、内漏、再干预和死亡率比较无显著差异。

临床怎么用

  • 原文结论认为Castor单分支覆膜支架在胸主动脉疾病治疗中显示出良好的早中期结局。
  • 原文结论认为将Castor覆膜支架与其他先进技术联合用于多分支主动脉弓重建是可行的。
  • 原文指出Castor覆膜支架作为一种货架型分支覆膜支架、型号广泛,也可用于大多数紧急情况,并预计未来将得到更广泛应用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The aim of this study was to evaluate the midterm efficacy and safety of a single-branch Castor stent graft in the treatment of thoracic aortic disease. MATERIALS AND METHODS: Clinical data of 106 patients with thoracic aortic disease treated with Castor single-branch stent graft at 3 centers were collected between May 2018 and June 2023. The indicators included technical success, stent-related complication, reintervention, retrograde dissection, endoleak, distal stent graft-induced entry (dSINE), branch patency, and mortality. The outcomes of the Castor stent graft for multibranch reconstruction above the arch was also analyzed. RESULTS: The technical success was 98.1% (104/106), while the surgical success was 93.4% (99/106). The reintervention was 2.8% (3/106), consisting of a case of retrograde type A dissection, an endoleak, and a dSINE. The retrograde dissection was 1.9% (2/106), while type I endoleak was 1.9% (2/106). The new dSINE was 2.8% (3/106), and the branch patency rate was 100%. The mortality was 1.9% (2/106). The mean follow-up time was 29.1±17.7 months. The 2-year post-surgery cumulative survival rate was 91.0%±3.1%, while the cumulative branch patency rate was 96.2%±2.2%. In addition, the cumulative freedom from stent-related reintervention rate was 93.2%±2.8%. A comparison showed no significant difference in the stent-related complication, branch patency, endoleak, reintervention, and mortality when the proximal end of the Castor stent graft was anchored to zones 1 or 2 of the aorta. CONCLUSION: Castor single-branch stent graft showed favorable early and midterm outcomes in the treatment of thoracic aortic disease. In addition, it was feasible to combine Castor stent graft with other advanced techniques for multibranch aortic arch reconstruction.Clinical ImpactThe Castor single-branch stent graft was approval by the Chinese Food and Drug Administration in 2017. However, there were few studies on the mid-term outcomes for thoracic aortic disease after launching, which mainly focused on small single-center retrospective study. In the study, we assessed the mid-term outcomes of Castor stent graft through multi-center cases, Castor stent graft combined with other advanced techniques (such as fenestration and hybrid) for multi-branch reconstruction of aortic arch were also conducted. We found Castor single-branch stent graft showed favorable early and mid-term outcomes in the treatment of thoracic aortic disease. Additionally, it was feasible to combine Castor stent graft with other advanced technique for multi-branch aortic arch reconstruction. As an off-the-shelf branched stent graft with a wide range of models, it could be also used in most emergent situation. The Castor stent graft was expected to become more widely used in the future.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Ren J, Chen Y, E E, et al. Midterm Outcomes of Multicenter Castor Single-Branch Stent Graft Use in the Treatment of Thoracic Aortic Diseases. J Endovasc Ther. 2024. PMID: 38414233. doi:10.1177/15266028241234500

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。